Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a growing threat to the health of many in their second or third age around the world \[[@CR1]\]. Unfortunately, coronary artery disease (CAD), which is responsible for a high percentage of all deaths globally, is often also a long-term complication of T2DM \[[@CR2]\]. Recently, research has shown an important link between a low testosterone level and the development of atherosclerosis in male patients \[[@CR3]\]. However, the association between a low testosterone level and CAD/cardiovascular risk is still being debated \[[@CR4]\]. Therefore, by comparing CAD rates in diabetic patients with low and normal testosterone levels at baseline, we aimed to systematically investigate this issue in male patients with T2DM.

Methods {#Sec2}
=======

Searched Databases and Strategies {#Sec3}
---------------------------------

The Cochrane database of randomized controlled trials, PubMed/Medline, and EMBASE were carefully searched for studies related to testosterone, diabetes mellitus, and CAD/cardiovascular risk using the search terms 'testosterone,' 'diabetes mellitus,' and 'cardiovascular disease.' The term 'cardiovascular disease' was later interchanged with the terms 'atherosclerosis' and 'coronary artery disease.' Abbreviations such as T2DM, DM, CVD, and CAD were also used to further enhance this search process. We only searched for articles published in English.

Inclusion and Exclusion Criteria {#Sec4}
--------------------------------

During this selection process, various inclusion and exclusion criteria were applied to all of the articles. The following inclusion criteria were used:Studies including only male patients with T2DMStudies comparing diabetic patients with low testosterone levels to diabetic patients with normal testosterone levelsStudies reporting the number of patients with CAD at baseline or during the follow-up period

The exclusion criteria were as follows:Studies that did not focus on male patients with T2DMStudies that did not compare diabetic patients with low testosterone levels to diabetic patients with normal testosterone levelsStudies that did not report the number of patients with CAD at baseline or during the follow-up period.

Endpoints {#Sec5}
---------

The only endpoint in this analysis was CAD/atherosclerosis/coronary plaque/major adverse coronary event prior to or following testosterone reduction.

Outcomes that were considered relevant in each study are recorded in Table [1](#Tab1){ref-type="table"}.Table 1Cardiovascular outcomes reported in the studies of interestStudyCardiovascular outcome reportedTime periodCheung et al. (2016) \[[@CR7]\]Coronary heart diseaseAt baselineFarias et al. (2014) \[[@CR8]\]Coronary plaqueAt baselineGianatti et al. (2016) \[[@CR9]\]Cardiovascular riskAt baselineHackett et al. (2016) \[[@CR10]\]Major adverse coronary eventsAt baselineLiu et al. (2013) \[[@CR11]\]Coronary artery diseaseAt baselineMuraleedharan et al. (2013) \[[@CR12]\]Pre-existing coronary vascular diseaseAt baseline

Data Extraction and Review {#Sec6}
--------------------------

The PRISMA guideline was followed \[[@CR5]\]. The studies were carefully checked and important relevant data were extracted by the reviewer (FH). The following data were extracted and cross-checked again:Author namesYear of publicationThe type of study performed (randomized trial or observational cohort);The total numbers of patients with low and normal testosterone levelsBaseline characteristics of the patientsThe patient enrollment periodThe testosterone level ranges that were considered to be low and normalThe total number of patients with CAD

Statistical Analysis {#Sec7}
--------------------

The analytical parameters used were the risk ratio (RR) and the 95% confidence interval (CI) obtained using the RevMan 5.3 software.

Heterogeneity was assessed via the *Q* statistic test and the *I*^2^ statistic test \[[@CR6]\].

A *P* value of ≤ 0.05 was assumed to indicate statistical significance.

A fixed effects model (*I*^2^ \< 50%) or a random effects model (*I*^2^ \> 50%) was used depending on the value of *I*^2^ obtained. In this analysis, both a fixed effects and a random effects were used during the subgroup assessment.

Sensitivity analyses were also carried out by excluding each of the studies in turn and conducting a new analysis following each exclusion.

Ethics {#Sec8}
------

The meta-analysis reported here was based on previously conducted studies and did not include any studies with human participants or animals performed by any of the authors. Hence, ethical approval was not required.

Results {#Sec9}
=======

Searched Results {#Sec10}
----------------

Two hundred forty-nine (249) articles were obtained during the database search. After two reviewers had carefully reviewed the abstracts, 228 publications were excluded since they were either not directly related to the present research or they were duplicates. Twenty-one (21) full-text articles were assessed for eligibility. Further articles were eliminated for the following reasons:One article was a review articleTen articles reported studies that did not involve male patients with T2DMFour articles did not report the relevant study endpoint

Finally, only six articles \[[@CR7]--[@CR12]\] were selected for the present analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram representing the study selection process

General Features of the Studies {#Sec11}
-------------------------------

A total of 3467 male patients with T2DM (1079 patients with a low testosterone level versus 2388 patients with a normal testosterone level) were included in this analysis (Table [2](#Tab2){ref-type="table"}). Two randomized trials and four observational cohorts were considered. The patient enrollment period varied between the years 2002 and 2013. The ranges of testosterone levels along with other features of the studies included in this analysis are listed in Table [2](#Tab2){ref-type="table"}.Table 2General features of the studies consideredStudyType of studyPatient enrollment period (years)No. of patients with low TT (*n*)No. of patients with normal/high TT (*n*)Low and normal/high TT rangesCheung et al. (2016) \[[@CR7]\]Observational2008--20111521087\< 9 and ≥ 9 nmol/LFarias et al. (2014) \[[@CR8]\]Observational2010--20123578\< 12.1 and ≥ 12.1 nmol/LGianatti et al. (2016) \[[@CR9]\]RCT2009--20134343ExogenousHackett et al. (2016) \[[@CR10]\]RCT2007--2009362320≤ 12 and \> 12 nmol/LLiu et al. (2013) \[[@CR11]\]Observational2008249517\< 300 and ≥ 300 ng/dLMuraleedharan et al. (2013) \[[@CR12]\]Observational2002--2005238343≤ 10.4 and \> 10.4 nmol/L*TT* testosterone, *RCT* randomized controlled trial

Baseline Characteristics of the Patients {#Sec12}
----------------------------------------

A summary of the baseline characteristics of the patients is shown in Table [3](#Tab3){ref-type="table"}. Mean age ranged from 58.0 to 65.6 years. Duration of diabetes mellitus ranged from 6 to 10.5 years. In addition, during a two-month control phase, glycosylated hemoglobin ranged between 6.80% and 7.90%. In terms of the baseline characteristics of the patients, there was almost no difference between the diabetic patients with low testosterone and those with normal testosterone levels.Table 3Baseline characteristics of the patients in each studyStudyAge (years)Disease duration (years)HBA1c (%)LDL^a^TC^b^Testosterone levelLT/NTLT/NTLT/NTLT/NTLT/NTCheung et al. (2016) \[[@CR7]\]60.4/58.410.0/10.07.90/7.702.43/2.604.48/4.55\< 9 vs ≥ 9 nmol/LFarias et al. (2014) \[[@CR8]\]59.0/58.07.90/6.007.05/6.90127/118--\< 12.1 vs ≥ 12.1 nmol/LGianatti et al. (2016) \[[@CR9]\]62.0/62.07.00/9.006.80/7.102.30/2.204.20/4.5010.6 vs 11.0 nmol/LHackett et al. (2016) \[[@CR10]\]65.5/64.2--7.50/7.30--4.10/4.10≤ 12.0 vs \> 12.0 nmol/LLiu et al. (2013) \[[@CR11]\]65.6/60.510.50/10.307.40/7.3086.7/92.3154/160.1240 vs 420 ng/dLMuraleedharan et al. (2013) \[[@CR12]\]60.3/58.9--7.50/7.20----7.5 vs 15.7 nmol/L*LT* low testosterone, *NT* normal testosterone, *LDL* low-density lipoprotein, *TC* total cholesterol,*vs* versus^a^Reported in mmol or mg/dL

Association of a Low Testosterone Level with Cardiovascular Risk {#Sec13}
----------------------------------------------------------------

The results of this analysis showed that when a random effects model was used, diabetic patients with a low testosterone level were at a relatively high risk of CAD/cardiovascular disease (RR 1.24, 95% CI 0.94--1.63; *P* = 0.13; Fig. [2](#Fig2){ref-type="fig"}). However, the difference in CAD/cardiovascular disease risk between the low and normal testosterone T2DM patients was not statistically significant.Fig. 2Association of a low testosterone level with cardiovascular risk (using the random effects model)

Similarly, when a fixed effects model was used, diabetic patients with a low testosterone level again were at a higher risk of CAD/cardiovascular disease than the diabetic patients with a normal testosterone level (RR 1.12, 95% CI 0.98--1.34; *P* = 0.08; Fig. [3](#Fig3){ref-type="fig"}). In this case, even though the difference in CAD/cardiovascular disease risk between the low and normal testosterone T2DM patients was again not statistically significant, it did approach significance.Fig. 3Association of a low testosterone level with cardiovascular risk (using the fixed effects model)

Sensitivity analysis was also carried out in order to confirm that the results of this analysis were not strongly influenced by the results from one of the studies in particular (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Results of a sensitivity analysis performed using the exclusion method

The sensitivity analysis showed that the results of the analysis did not change significantly when any one of the following studies was excluded from the analysis: Cheung et al. \[[@CR7]\] (RR 1.15, 95% CI 0.88--1.52; *P* = 0.31), Farias et al. \[[@CR8]\] (RR 1.17, 95% CI 0.85--1.61; *P* = 0.33), Gianatti et al. \[[@CR9]\] (RR 1.18, 95% CI 0.90--1.55; *P* = 0.23), Hackett et al. \[[@CR10]\] (RR 1.31, 95% CI 0.97--1.78; *P* = 0.08), and Muraleedharan et al. \[[@CR12]\] (RR 1.30, 95% CI 0.88--1.93; *P* = 0.19). However, when the study by Liu et al. \[[@CR11]\] was excluded, T2DM patients with a low testosterone level were found to be at a significantly higher risk of cardiovascular disease than those with a normal testosterone level (RR 1.35, 95% CI 1.02--1.78; *P* = 0.04).

Discussion {#Sec14}
==========

Through this analysis, we aimed to show whether a decreased testosterone level was associated with a higher risk of CAD/cardiovascular disease in male patients with T2DM. Our results suggested that such a link was present, although, due to a lack of statistical significance, there was not enough evidence to prove this link.

Testosterone, which is derived from cholesterol, is the male sex hormone \[[@CR13]\]. In the body, most testosterone is bound to protein (about 98%), while some is present as free molecules (about 2%). The free testosterone is readily available in the blood and is responsible for several major important functions in the male body. It is primarily synthesized in Leydig cells in the testes of the male sex organ \[[@CR14]\]. In men, testosterone is responsible for secondary sexual features, it increases libido (sex drive), and it improves erectile function. It is also important for maintaining healthy vascular function throughout the body \[[@CR15]\] and has other important functions which will not be discussed here \[[@CR16]\]. A few studies have even shown testosterone to be modestly cardioprotective; possible mechanisms for this cardioprotective action have been proposed \[[@CR17]\] and are listed in Table [4](#Tab4){ref-type="table"}.Table 4Main mechanisms that link testosterone level to the risk of coronary artery diseaseTestosterone\...1. Acts as an anti-arrhythmic agent, so it is cardioprotective2. Reduces the size of a MI, so it is cardioprotective3. Causes vasodilation of coronary vessels, so it is cardioprotective4. May decrease QTc interval in the electrocardiogram5. Prevents plaque formation, thus protecting from atherosclerosis6. Reduces visceral fat accumulation and improves fasting glucose levels7. May, according to some controversial reports, lead to blood vessel constriction at high doses, and may also increase inflammation, which could aggravate MI*CAD* coronary artery disease, *MI* myocardial infarction

In brief, a high testosterone concentration may have anti-arrhythmic properties \[[@CR17]\]. Testosterone might also decrease the QTc interval length, thus exerting a beneficial cardiovascular effect. This hormone may also reduce the size of an infarction in the cardiac muscle, further showing that it is cardioprotective. Studies have also shown that testosterone causes blood vessel vasodilation, which again has a positive effect on the cardiovascular system. Further, testosterone has been found to prevent plaque formation, thus protecting from atherosclerosis \[[@CR17]\].

The association of a low testosterone level with CAD/cardiovascular disease is still controversial \[[@CR4]\]. However, in support of the results of the present analysis, a Japanese study showed a direct link between testosterone deficiency and cardiovascular events \[[@CR18]\]. The authors concluded that a low testosterone level was associated with cardiovascular events in middle-aged Japanese men, independent of coronary risk factors and endothelial function. In addition, a 13-year follow-up of former multiple risk factor intervention trial participants showed that a decreased endogenous testosterone level in men was associated with potentially unwanted changes in triglyceride level (increased) and high density lipoprotein (decreased), which could contribute to cardiovascular disease \[[@CR19], [@CR20]\].

Furthermore, Donner et al. found that a testosterone deficiency in diabetic patients was related to cardiovascular risk or outcomes \[[@CR21]\]. However, their study was limited to animal models in which cardiovascular structure and function as well as myocardial tolerance were investigated. Daka et al. also showed that a low testosterone level predicted acute myocardial infarction in Swedish male patients with T2DM \[[@CR22]\].

On the other hand, Hernández-Mijares et al. did not find any association between low testosterone and the risk of silent myocardial infarction or peripheral artery disease, even though their study showed that a low level of testosterone in diabetic male patients was associated with a high body mass index, a high waist circumference, neuropathy, and other unwanted conditions \[[@CR23]\]. Nevertheless, a letter of correspondence to Hernández-Mijares et al. revealed that the use of oral hypoglycemic agents and other confounding factors may have contributed to the fact that no association was observed between cardiovascular risk and a low testosterone level in his patients with T2DM \[[@CR24]\].

It should also not be ignored that clinical research has shown that testosterone interacts with thrombophilia-hypofibrinolysis, leading to thrombosis. So, decreasing the testosterone level would prevent testosterone-associated thrombosis, thus lowering the incidence of cardiovascular disease. Further, it is known that platelet aggregation and stimulation of the coagulation pathway play important roles in thrombus formation, and in vitro studies in animal models have shown that reducing testosterone decreases platelet aggregation and thromboxane A2 receptor density, thereby reducing the incidence of cardiovascular disease \[[@CR25]\]. Even when given at a physiological dosage, testosterone was shown to increase platelet aggregation \[[@CR26]\]. Apart from platelet aggregation, testosterone also promotes coagulation by affecting coagulation factors that are implicated in the fibrinolytic pathway, resulting in an increased level of plasminogen activator inhibitor-1 and thus a higher risk of cardiovascular manifestations due to reduced fibrinolysis \[[@CR27]\].

Oral hypoglycemic agents as well as statins have been found to affect the testosterone level in male patients with T2DM. While metformin is believed to reduce the total testosterone level in male patients with T2DM \[[@CR28]\], glimepiride might, in contrast, help to recover the decreased testosterone level \[[@CR29]\], whereas the involvement of statins in reducing the testosterone level is still doubtful \[[@CR30]\]. Some of the possible iatrogenic causes of testosterone modulation in patients with diabetes mellitus are given in Table [5](#Tab5){ref-type="table"}.Table 5Some of the possible iatrogenic causes of testosterone modulation in patients with diabetes mellitusMedications used in patients with diabetes mellitusEffect of the medications on the testosterone levelBiguanidesReduce itSulfonylureaStabilizes it at normal levelAlpha-glucosidase inhibitorsReduce itThiazolidinedionesReduce itInsulinStabilizes it at normal level

A decreased testosterone level has also been shown to increase vascular disease risk in men with hypogonadotropic hypogonadism by indirectly increasing triglyceride levels and low-density lipoprotein levels and decreasing high-density lipoproteins in the blood, which may ultimately contribute to the development of coronary artery disease \[[@CR31]\]. In men who are on antiandrogen therapy (for example patients with prostate cancer), a decreased testosterone level may indirectly contribute to cardiovascular diseases, as previously mentioned \[[@CR32]\]. In patients with diabetes mellitus, other factors involving different mechanisms could further raise low-density lipoprotein levels and promote platelet hyperactivity, contributing to cardiovascular diseases \[[@CR33]\].

Nevertheless, cardiovascular disease is one of the main complications that arise in patients with diabetes mellitus. Thus, we believe that the time has come to review the relationship between testosterone level and cardioembolism, given that the testosterone level decreases with age and the use of testosterone ointment by the elderly is rising due to an increased rate of erectile dysfunction.

Novelty {#Sec15}
-------

This study is new because it is the first meta-analysis to show that a low level of testosterone is a risk factor for CAD/cardiovascular disease in patients with T2DM. The results of this study may inspire other scientists to investigate this matter further, given that this is potentially an important finding that could be utilized in clinical medicine. Finally, since it is a new idea in the field of cardiovascular diabetology, this analysis is a novelty in itself.

Limitations {#Sec16}
-----------

The limited sample size of the population analyzed may have influenced the results. In addition, one of the studies considered in this meta-analysis also involved patients who were being treated with testosterone; however, because that study satisfied the inclusion and exclusion criteria, it was included in the analysis. Moreover, a moderate level of heterogeneity was observed during the subgroup analysis. This may have been due to the inclusion of observational data and other heterogeneous reported data. Also, the range of testosterone levels varied depending on the study, which could be another major limitation of this analysis. In addition, the analysis only focused on a particular subgroup of patients with T2DM who did not represent the general population of patients. Another limitation is the fact that old age is associated with a decreased level of testosterone; this would have acted as a confounding factor, possibly affecting the results.

Conclusion {#Sec17}
==========

A previously or currently decreased testosterone level did not show a statistically significant association with a higher risk of CAD/cardiovascular disease in male patients with T2DM, although the difference in risk between the T2DM patients with low and normal testosterone levels was observed to approach statistical significance. The limited number of patients analyzed was not sufficient to prove this association, thus warranting further investigations.
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